Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.82
-1.00 (-6.75%)
Sep 15, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Employees
Contineum Therapeutics had 51 employees as of December 31, 2025. The number of employees increased by 10 or 24.39% compared to the previous year.
Employees
51
Change (1Y)
10
Growth (1Y)
24.39%
Revenue / Employee
n/a
Profits / Employee
-$1,128,588
Market Cap
519.92M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 51 | 10 | 24.39% |
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| REGENXBIO | 371 |
| Arvinas | 246 |
| ProKidney | 231 |
| Capricor Therapeutics | 231 |
| Assembly Biosciences | 73 |
| Tectonic Therapeutic | 60 |
| Eupraxia Pharmaceuticals | 49 |
CTNM News
- 15 hours ago - Contineum Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 1 day ago - Contineum price target lowered to $24 from $26 at Jones - TheFly
- 1 day ago - Contineum price target lowered to $19 from $20 at Baird - TheFly
- 1 day ago - Contineum, J&J's depression drug fails to meet mid-stage trial goal - Reuters
- 1 day ago - Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint - TheFly
- 1 day ago - Contineum down 11% atter MOONLIGHT-1 trial did not achieve endpoint - TheFly
- 1 day ago - Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder - Business Wire
- 21 days ago - Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference - Business Wire